Medicare Coverage of Technology, 1999-2007 How Evidence-Based, Timely, and Flexible? June 10, 2008 Peter J. Neumann, Maki S. Kamae, Jennifer A. Palmer.

Slides:

Advertisements

Similar presentations

THE COMMONWEALTH FUND Developing Innovative Payment Approaches: Finding the Path to High Performance Stuart Guterman Vice President, Payment and System.

Advertisements

Medicare Transmittal 956 CR 5124 May 19, 2006 NOPR Billing Instruction Clarification – Physician Offices/IDTF use QR Modifier – Hospitals use QR and V70.7.

REACH Healthcare Foundation Prepared by Mid-America Regional Council 2013 Kansas City Regional Health Assessment.

The Latest Federal Initiatives in Evidence-Based Medicine Barry M. Straube, M.D. Centers for Medicare & Medicaid Services Citizen’s Council on Health Care.

429 pharmaceutical care Plan Refa’a AlAjmi. Goal of therpay A goal of therapy is the desired response or endpoint that you and your patient want to achieve.

World Health Organization

March 3, 2014 IN SIXTY: Cancer Patient Journey. RELEASE AVAILABLE AT:

Turning Questions into Trials: Innovation in Surgical Oncology Jennifer E. Rosen MD FACS Assistant Professor of Surgery and Molecular Medicine Boston University.

Primary Prevention ICD Therapy: Tools to Enhance Guideline Compliance By: Margaret S. Thomas, RN,CVRN Michael J. Mirro, MD Alicia S. Floor, AS,RN, Rob.

CADTH Therapeutic Reviews

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.

Identification & Distinction of Clinical Trial Participant Charges Bethany Martell Office of Clinical Research Associate Director- Financial Operations.

CER Needs from a state health policy perspective: California Health Benefits Review Program Susan Philip, MPP California Health Benefits Review Program.

Cancer Program Standards 2012: Ensuring Patient-Centered Care

Medical Devices Approval Process

1 Drug and Therapeutics Committee Session 10. Standard Treatment Guidelines.

Medicare Modifiers: The Impact on Clinical Research Susie Bullock, RN, MPH, OCN, CCRP Manager Clinical Research Support Center MD Anderson Cancer Center.

Positron Emission Tomography (PET) Scans in Ovarian Cancer Effectiveness of PET Scans and Recommendations for CMS August 20, 2008 Ovarian Cancer National.

Valuing Medical Technologies The Decision Maker Perspective.

Standard 5: Patient Identification and Procedure Matching Nicola Dunbar, Accrediting Agencies Surveyor Workshop, 10 July 2012.

Critical Appraisal of Clinical Practice Guidelines

CMS Future HAC Plans? HAI Cost Impact on Hospitals? Rick Sites General Counsel & Senior Health Policy Director October 1, 2008.

Medicare’s Disease Management Activities Stuart Guterman Director, Office of Research, Development, and Information Centers for Medicare & Medicaid Services.

Presenter-Dr. L.Karthiyayini Moderator- Dr. Abhishek Raut

Comparative Effectiveness in Orthopaedics: Stakeholder Perspectives Kevin J. Bozic, MD, MBA Associate Professor and Vice Chair UCSF Department of Orthopaedic.

Getting Better Value in Health Care Public Employers Health Purchasing Committee 5-23 DRAFT.

Comparative Effectiveness Research: Payer Perspectives 1 Sean Tunis MD, MSc May 5, 2009.

Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.

The Safety, Efficacy, and Durability of Lung Volume Reduction Surgery: A 10-Year Experience Mark E. Ginsburg, MD, Byron M. Thomashow, MD, William M. Bulman,

Coverage with Evidence Development Implantable Cardioverter Defibrillators 1 Sean Tunis MD, MSc June 23, 2009.

Medicare Preventive Services Marcel Salive, MD, MPH, FACPM Coverage and Analysis Group, OCSQ Director, Division of Medical and Surgical Services.

CMS as a Public Health Agency: Effective Health Care Research Barry M. Straube, M.D. Centers for Medicare & Medicaid Services January 11, 2006.

Secondary Translation: Completing the process to Improving Health Daniel E. Ford, MD, MPH Vice Dean Johns Hopkins School of Medicine Introduction to Clinical.

Plymouth Health Community NICE Guidance Implementation Group Workshop Two: Debriding agents and specialist wound care clinics. Pressure ulcer risk assessment.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.

1 “CATCH-22” INTENDED USE DEFINITION The FDA and CMS: Changes in Regulatory and Surveillance Proximity Beverly H. Lorell, MD, FACC Senior Medical & Policy.

Evidence, HTA and Comparative Effectiveness in the U.S. Presentation at AMCP March 28, 2007 Peter J. Neumann Tufts-New England Medical Center.

Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Reimbursement: A Look Inside the Black Box Eric L. Book, MD March 27,

1 The Role of Medicare National Coverage in the Regulatory Process Steve Phurrough MD, MPA Director, Coverage and Analysis Group Centers for Medicare and.

Industry Prospective Robin Bostic, Thoratec VP Health Policy and Health Economics INTERMACS Industry Sub-Committee Representative Our Future.

DataBrief: Did you know… DataBrief Series ● October 2011 ● No. 21 Dual Eligibles, Chronic Conditions, and Functional Impairment In 2006, 37% of seniors.

Improving Value in Health Care: Challenges and Potential Strategies Arnold M Epstein October 24, 2008 Congressional Health Care Reform Education Project.

The Second Annual FDA Regulatory and Compliance Symposium Managing Risks – From Pipeline to Patient Policy Implications of Greater FDA/CMS Collaboration.

1 National Forum on Biomedical Imaging in Oncology CMS UPDATE Steve Phurrough MD, MPA Director, Coverage and Analysis Group.

GERIATRIC EDUCATION SERIES Presented in partnership by Funded in part by a grant from the EJC Foundation.

HTA Efficient Study Designs Peter Davidson Head of HTA at NETSCC.

The US Preventive Services Task Force: Potential Impact on Medicare Coverage Ned Calonge, MD, MPH Chair, USPSTF.

The Cancer Registry of Norway Jan F Nygård Head of the IT-department.

Advanced Healthcare Technology Management Workshop Mombasa, Kenya — 9-12 August 2006 IFHE Health Technology Assessment Jennifer McGill, M.Eng., CCE.

Evidence in the Coverage Process: An Evolving Paradigm Kevin Schulman, M.D. Director, Center for Clinical and Genetic Economics Duke University Medical.

Copyright © 2009 by The McGraw-Hill Companies, Inc. All Rights Reserved. McGraw-Hill/Irwin Chapter 2 Clinical Information Standards – Unit 3 seminar Electronic.

Intersecting roles CMS and FDA – implications for pharmaceutical and device industries Peter B. Bach, MD, MAPP Senior Adviser, Office of the Administrator.

Assessing and Improving the Quality of Care For Low Back Pain

MedStar Washington Hospital Center Cardiac Catheterization Conference

Defibrillator in Acute Myocardial Infarction Trial

Annual Outcomes With Transcatheter Valve Therapy

Medtech in Transition: Where Are We Now and What Lies Ahead

Coverage with Evidence Development (CED)

Annual Outcomes With Transcatheter Valve Therapy

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

CMS/Coverage and Analysis Group

Towards International Harmonized Nomenclature for Medical Devices

Megan Eguchi, MPh Sana karam, md, phd

Creation of an Independent Medicare Advisory Council

A Population Level Analysis of Statewide Claims Data

HEART-LUNG TRANSPLANTATION

Presentation transcript:

Medicare Coverage of Technology, How Evidence-Based, Timely, and Flexible? June 10, 2008 Peter J. Neumann, Maki S. Kamae, Jennifer A. Palmer Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA Support from the Commonwealth Fund

Key Dates in Medicare National Coverage 1965Medicare establishes (“reasonable and necessary” criteria) 1989Proposed coverage reg with CEA 1998MCAC created (renamed MEDCAC) 1999CMS begins posting NCDs on web 2003Medicare Modernization Act CED guidance

Quality of evidence available to Medicare Consistency of decisions with evidence; Timeliness of Medicare coverage Factors impacting decisions & review times CMS use of CED Objectives

Data and Methods Reviewed all complete Medicare NCDs from (n=119) Each NCD memo reviewed independently by 2 investigators Detailed information extracted (~30 variables each)

CMS Coverage Page

Recent Examples of NCDs ICD for sudden death prophylaxis Artificial hearts Erythropoiesis stimulating agents Lumbar artificial disc replacement CPAP for obstructive sleep apnea

Definition of Evidence Classification Good Evidence includes consistent results from well-designed studies Fair Evidence sufficient to determine effect on health outcomes Strength of evidence is limited Poor Evidence is insufficient to assess the effects on health outcome Strength of evidence is very limited Source: Adapted from USPSTF.

Number of NCDs by Year (N=119) Medicare Modernization Act (MMA) Number of NCDs

Characteristics of National Coverage Decisions, Type of technology Total (n=119) Medical procedure24% Medical device18% Laboratory test14% Imaging12% Surgical procedure11% Other medical therapy10% Drugs8% Health education/behavior3%

Direction of Decisions (n=119)

Type of conditions placed on favorable coverage decisions a Total (n=119) Restricted to patients with defined disease severity56% Diagnostic test restricted by specific test threshold25% Restricted to patients receiving care in specific care settings17% Restricted to patients meeting clinical trial criteria12% Coverage with evidence development Other 6% 16% Characteristics of National Coverage Decisions, a Not mutually exclusive.

Strength of Evidence (n=119)

Strength of Evidence and Direction of Decision Number of decisions

MEDCAC use, MEDCAC = Medicare Evidence Development & Coverage Advisory Committee

HTA = Health Technology Assessment

Time to decision by MEDCAC and HTA Proportion with no Decision MEDCAC or HTA Neither MEDCAC nor HTA MEDCAC and HTA Time (days) Median 233 days Median 350 days Median 457 days PET (FDG) for Alzheimer's Disease/Dementia Radioimmunotherapy for Non- Hodgkin's Lymphoma Cardiac Catheterization Performed In Other Than A Hospital Setting

Proportion with no Decision Time (days) Good evidence, No MEDCAC/HTA Fair/Poor evidence, No MEDCAC/HTA Good evidence, with MEDCAC/HTA Fair/Poor evidence, with MEDCAC/HTA Log Rank P <.0001 Time to Decision by Strength of Evidence and MEDCAC/HTA Median 233 days Median 251 days Median 432 days Median 359 days

Time to Decision by before / after MMA Proportion with no Decision Before MMA Time (days) Median 249 days Median 265 days N=119 Log Rank P=0.029 After MMA

Time to Decision by Direction of Coverage Time (days) Proportion with no Decision Covered (with or without restriction) No National Coverage Log Rank P = Median 269 days Median 255 days

National Coverage DeterminationDate Lung volume reduction surgery2003 PET for dementia2004 Cochlear implantation2005 Implantable defibrillators2005 Chemotherapy for colorectal cancer2005 PET for cancer2005 Home use of oxygen2006 CED Cases,

Key Findings The quality of evidence available to CMS for most technologies is no better than fair. Still, CMS has covered in 60% of cases, though almost always with conditions. Involvement of MEDCAC is relatively infrequent and prolongs review times. Since MMA all decisions have met review time standards. CMS has issued 7 CED decisions, 5 with active trials or registries.

Policy Implications Need for better evidence Tradeoffs between rigor and timeliness CED promising but implementation challenges No explicit cost-effectiveness but $$ matter